Ruxience

Generic name: rituximab-pvvr

Used for: Non-Hodgkin lymphoma (NHL) · Chronic lymphocytic leukemia (CLL) · Rheumatoid arthritis · Blood vessel inflammation (GPA and MPA) · Pemphigus vulgaris (a blistering skin disease) · 4 more

Ruxience is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Ruxience is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameRuxience
Authorized genericrituximab-pvvr
Regular genericrituximab-pvvr
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Ruxience?
The original
–
–

Brand nameThe maker’s card

Pfizer Oncology Together Co-Pay Savings Program for Injectables / Pfizer enCompass Co-Pay Assistance Program for RUXIENCE

Savings card from Pfizer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

The card takes up to $4,000–$10,000 a year off your co-pay.

Sign up on pfizercopay.com 

Or call 1-800-555-4820.

In the maker’s words

“as little as $0 per administered dose.”

From the maker’s offer on pfizercopay.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Ruxience itself, from the same company, sold without the brand name, and usually for less. For now Ruxience is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Ruxience is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

RUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of:

  • Adult patients with Non-Hodgkin's Lymphoma (NHL).
    • Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent.
    • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
    • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
    • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
  • Adult patients with Chronic Lymphocytic Leukemia (CLL).
    • Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
  • Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies.
  • Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids.
  • Moderate to severe Pemphigus Vulgaris (PV) in adult patients.

Source: the FDA label for Ruxience (Pfizer Laboratories Div Pfizer Inc), October 2, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/ruxience/